Boehringer Ingelheim licensed a preclinical antibody program from Immunitas to advance treatments for chronic inflammatory disease.
Immunitas Therapeutics is a biotechnology company dedicated to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases
Immunitas Therapeutics is a biotechnology company dedicated to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Their lead program, IMT-009, targets CD161 and is currently in clinical trials for patients with refractory tumors across various indications, including colorectal cancer, head and neck cancer, and non-small cell lung cancer.